CNS Pharmaceuticals, Inc. — All Filings
368 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
1-A
1-A-W
1-A/A
10-K
10-K/A
10-Q
3
4
4/A
424B3
424B4
424B5
8-A12B
8-K
8-K/A
ARS
C
C-AR
C-TR
C-U
CERT
CORRESP
DEF 14A
DEFA14A
DEFR14A
DOS
DRS
DRSLTR
EFFECT
FWP
PRE 14A
RW
S-1
S-1/A
S-3
S-8
SC 13D
SC 13G
SC 13G/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | CURRENT REPORT | 0001683168-26-001664 | Mar 11, 2026 | — |
| 4 | — | 0001683168-26-001491 | Mar 4, 2026 | Mar 2, 2026 |
| 3 | — | 0001683168-26-001490 | Mar 4, 2026 | Mar 2, 2026 |
| 4 | — | 0001683168-26-001489 | Mar 4, 2026 | Mar 2, 2026 |
| 3 | — | 0001683168-26-001488 | Mar 4, 2026 | Mar 2, 2026 |
| 8-K | FORM 8-K | 0001683168-26-001413 | Mar 2, 2026 | Feb 26, 2026 |
| S-8 | FORM S-8 | 0001683168-26-001368 | Feb 27, 2026 | — |
| 8-K | FORM 8-K | 0001683168-26-001066 | Feb 17, 2026 | Feb 10, 2026 |
| SCHEDULE 13G/A | — | 0000935836-26-000092 | Feb 13, 2026 | — |
| 4 | — | 0001683168-26-000016 | Jan 2, 2026 | Jan 1, 2026 |
| 3 | — | 0001683168-26-000014 | Jan 2, 2026 | Jan 1, 2026 |
| 8-K | CURRENT REPORT | 0001683168-25-009208 | Dec 17, 2025 | Dec 16, 2025 |
| 8-K | CURRENT REPORT | 0001683168-25-008624 | Nov 21, 2025 | Nov 17, 2025 |
| 4 | — | 0001683168-25-008576 | Nov 19, 2025 | Nov 17, 2025 |
| 4 | — | 0001683168-25-008566 | Nov 19, 2025 | Nov 17, 2025 |
| 4 | — | 0001683168-25-008564 | Nov 19, 2025 | Nov 17, 2025 |
| 4 | — | 0001683168-25-008565 | Nov 19, 2025 | Nov 17, 2025 |
| 4 | — | 0001683168-25-008563 | Nov 19, 2025 | Nov 17, 2025 |
| 4 | — | 0001683168-25-008562 | Nov 19, 2025 | Nov 17, 2025 |
| 4 | — | 0001683168-25-008561 | Nov 19, 2025 | Nov 17, 2025 |
| SCHEDULE 13G/A | — | 0001172661-25-005174 | Nov 14, 2025 | — |
| 10-Q | FORM 10-Q FOR SEP 2025 | 0001683168-25-008466 | Nov 14, 2025 | Sep 30, 2025 |
| DEFA14A | FORM DEFA14A | 0001683168-25-008266 | Nov 12, 2025 | — |
| SCHEDULE 13G | — | 0000935836-25-000648 | Nov 4, 2025 | — |
| ARS | ANNUAL REPORT | 0001683168-25-007794 | Oct 28, 2025 | Dec 31, 2024 |
| DEF 14A | DEF 14A | 0001683168-25-007760 | Oct 24, 2025 | Nov 17, 2025 |
| PRE 14A | PRELIMINARY PROXY STATEMENT | 0001683168-25-007498 | Oct 10, 2025 | Nov 17, 2025 |
| 424B5 | SUPPLEMENT NO. 3 TO PRO SUPP DATED 7-26-24 | 0001683168-25-007157 | Sep 19, 2025 | — |
| SCHEDULE 13G | — | 0001172661-25-003572 | Aug 14, 2025 | — |
| 10-Q | FORM 10-Q FOR JUN 2025 | 0001683168-25-006162 | Aug 14, 2025 | Jun 30, 2025 |
| 8-K | FORM 8-K | 0001683168-25-005284 | Jul 22, 2025 | Jul 17, 2025 |
| 8-K | FORM 8-K | 0001683168-25-005129 | Jul 15, 2025 | — |
| 10-Q | FORM 10-Q FOR MAR 2025 | 0001683168-25-003733 | May 15, 2025 | Mar 31, 2025 |
| 8-K | FORM 8-K | 0001683168-25-003575 | May 15, 2025 | May 13, 2025 |
| 424B4 | FORM 424B4 | 0001683168-25-003523 | May 14, 2025 | — |
| EFFECT | — | 9999999995-25-001564 | May 13, 2025 | — |
| CORRESP | — | 0001683168-25-003396 | May 12, 2025 | — |
| CORRESP | — | 0001683168-25-003394 | May 12, 2025 | — |
| S-1/A | AMENDMENT NO. 1 TO FORM S-1 | 0001683168-25-003362 | May 12, 2025 | — |
| 10-K/A | AMENDMENT NO. 1 TO FORM 10-K | 0001683168-25-002998 | Apr 30, 2025 | Dec 31, 2024 |
| CORRESP | — | 0001683168-25-002657 | Apr 17, 2025 | — |
| CORRESP | — | 0001683168-25-002655 | Apr 17, 2025 | — |
| CORRESP | — | 0001683168-25-002552 | Apr 14, 2025 | — |
| CORRESP | — | 0001683168-25-002549 | Apr 14, 2025 | — |
| S-1 | FORM S-1 | 0001683168-25-002548 | Apr 14, 2025 | — |
| UPLOAD | — | 0000000000-25-003888 | Apr 11, 2025 | — |
| 8-K | FORM 8-K | 0001683168-25-002373 | Apr 9, 2025 | — |
| DRSLTR | — | 0001683168-25-002313 | Apr 7, 2025 | — |
| DRS | — | 0001683168-25-002312 | Apr 7, 2025 | — |
| 8-K | CURRENT REPORT | 0001683168-25-002140 | Mar 31, 2025 | — |